Cargando…

Pharmacogenomically actionable medications in a safety net health care system

OBJECTIVE: Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites. METHODS: Using 1-year electroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Janet S, Rosenman, Marc B, Knisely, Mitchell R, Decker, Brian S, Levy, Kenneth D, Flockhart, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724767/
https://www.ncbi.nlm.nih.gov/pubmed/26835014
http://dx.doi.org/10.1177/2050312115624333
_version_ 1782411583933120512
author Carpenter, Janet S
Rosenman, Marc B
Knisely, Mitchell R
Decker, Brian S
Levy, Kenneth D
Flockhart, David A
author_facet Carpenter, Janet S
Rosenman, Marc B
Knisely, Mitchell R
Decker, Brian S
Levy, Kenneth D
Flockhart, David A
author_sort Carpenter, Janet S
collection PubMed
description OBJECTIVE: Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites. METHODS: Using 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited. RESULTS: Results showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system. CONCLUSION: Findings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling.
format Online
Article
Text
id pubmed-4724767
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-47247672016-01-31 Pharmacogenomically actionable medications in a safety net health care system Carpenter, Janet S Rosenman, Marc B Knisely, Mitchell R Decker, Brian S Levy, Kenneth D Flockhart, David A SAGE Open Med Original Article OBJECTIVE: Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites. METHODS: Using 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited. RESULTS: Results showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system. CONCLUSION: Findings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling. SAGE Publications 2016-01-07 /pmc/articles/PMC4724767/ /pubmed/26835014 http://dx.doi.org/10.1177/2050312115624333 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Carpenter, Janet S
Rosenman, Marc B
Knisely, Mitchell R
Decker, Brian S
Levy, Kenneth D
Flockhart, David A
Pharmacogenomically actionable medications in a safety net health care system
title Pharmacogenomically actionable medications in a safety net health care system
title_full Pharmacogenomically actionable medications in a safety net health care system
title_fullStr Pharmacogenomically actionable medications in a safety net health care system
title_full_unstemmed Pharmacogenomically actionable medications in a safety net health care system
title_short Pharmacogenomically actionable medications in a safety net health care system
title_sort pharmacogenomically actionable medications in a safety net health care system
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724767/
https://www.ncbi.nlm.nih.gov/pubmed/26835014
http://dx.doi.org/10.1177/2050312115624333
work_keys_str_mv AT carpenterjanets pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem
AT rosenmanmarcb pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem
AT kniselymitchellr pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem
AT deckerbrians pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem
AT levykennethd pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem
AT flockhartdavida pharmacogenomicallyactionablemedicationsinasafetynethealthcaresystem